Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) made history when they brought their coronavirus vaccines from development to market in less than a year. So far, though, Moderna has been the only one to benefit from a share-price perspective. The company's shares soared more than 600% this year. Pfizer's stock is little changed.
Why such a difference? Investors knew that an eventual vaccine would be Moderna's first marketed product, and therefore, its source of product revenue. Conversely, Pfizer's future didn't depend on the vaccine program. That's because the big pharmaceutical company generates revenue from a vast array of products.
Now we've entered a new phase. Moderna and Pfizer launched their vaccines this month under emergency authorizations. Let's take a look at which company may win when it comes to revenue -- and share performance.
Source Fool.com
